L1 Global Long Short Fund Limited (GLS)
ASX ASX Primary Summary
L1 Global Long Short Fund Limited (GLS) FAQ
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has L1 Global Long Short Fund Limited ever had a stock split?
L1 Global Long Short Fund Limited Profile
| ASX Exchange | US Country |
Overview
Gelesis Holdings, Inc. was a commercial-stage biotherapeutics company focused on developing innovative solutions to combat obesity and gastrointestinal (GI)-related chronic diseases through biomimicry. Established in 2006 and based in Boston, Massachusetts, the company aimed to address some of the most pressing health issues of modern times with its unique approach towards weight management and GI health. Notably, on October 30, 2023, Gelesis Holdings, Inc., along with its affiliates, entered into a voluntary liquidation process under Chapter 7 of the U.S. Bankruptcy Court for the District of Delaware, marking the end of its operational journey.
Products and Services
- PLENITY
An innovative, non-systemic, and non-stimulant weight management aid designed for oral administration. PLENITY works by aiding in weight control, targeting adults with a Body Mass Index (BMI) in the overweight to obese range. It is an example of the company's dedication to providing solutions for weight management without the need for systemic drugs or stimulants, aligning with their biomimicry approach.
- GS200
In development for weight loss in individuals with prediabetes and type 2 diabetes, GS200 represents Gelesis Holdings, Inc.'s commitment to addressing the specific needs of patients dealing with metabolic disorders. This product aims to provide a targeted approach to weight management in a population at high risk for obesity-related complications.
- GS500
Targeted at improving outcomes for patients suffering from functional constipation, GS500 is another innovative product in the company's pipeline. It exemplifies Gelesis Holdings, Inc.'s efforts to expand their solutions beyond weight management and into the broader realm of gastrointestinal health, offering potential relief for a common GI issue.
- GS300
A pre-clinical product being developed for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). GS300 underscores the company's expansion into treating more severe GI-related chronic diseases through their biomimetic approach, targeting conditions with significant unmet medical needs.
